Inthera Bioscience AG

https://www.intherabio.com

Inthera Bioscience is a private biopharmaceutical company focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. Rationally designed, these orally bioavailable molecules display hot spot residues on a non-peptidic backbone merging the versatility of small molecules with the specificity of biologics. The broad applicability of the approach has been illustrated against several targets in oncology. Inthera’s lead programs focus on HPV-associated cancers and hypoxia-inducible signaling. *

	Start	2013-09-20 established
	Industry	small-molecule cancer drug
	Industry 2	drug development
	Person	Kessler, Ulrich (Inthera Bioscience AG 201512 CEO + Co-founder)
	Person 2	Schollmeier, Klaus (SuppreMol 201304– Managing Director before Santhera CEO + ING BHF-Bank + Abbott/Knoll/BASF)

	Region	Zürich ZH
	Country	Switzerland
	Street	11 Gartenstr.
	City	8002 Zürich ZH
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Inthera Bioscience AG. (5/31/17). "Press Release: Inthera Bioscience Raises CHF 10.5 Million in Series A Financing Round". Zurich.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Inthera Bioscience AG

[1] Inthera Bioscience AG. (5/31/17). "Press Release: Inthera Bioscience Raises CHF 10.5 Million in Series A Financing Round". Zurich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]